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Figure 1. PFS is decreased in patients who receive alemtuzumab
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Background: High-throughput sequencing (HTS) of anti-
body gene rearrangements is an emerging tool for minimal
residual disease (MRD) monitoring in B cell malignancies in
which the malignant clone harbors a monoclonal Ig heavy
chain (IgH) and/or light chain (k or l) rearrangement. This
approach has shown promise in B-ALL and CLL, but appli-
cation of Ig HTS to clinical multiple myeloma (MM) samples
has not been demonstrated previously.
Approach:We conducted HTS of PCR-ampliﬁed IgH (VDJ and
DJ) and k/l (VJ) rearrangements from bone marrow aspirates
(BMA) of patients with MM (n¼9), MGUS (n¼1), and lym-
phoplasmacytic lymphoma (n¼1), and peripheral blood (PB)
of a patient with plasma cell leukemia (n¼1). In 9/12 samples,
an aliquot was enriched for CD138+ cells by immunomagnetic
separation and analyzed separately. Dominant clones from
enriched and un-enriched aliquots were compared to verify
the malignant clonotype sequence. Disease burden in un-
enriched samples was also evaluated by microscopy (BMA/PB
smear) and ranged from 0 (hemodilute) to 37%.
Results: In 11/12 samples, a clearly dominant IgH and/or k/l
rearrangement (>2.7% of total sequences, range 2.7-99.9%)
was identiﬁed with clear separation from background fre-
quency (at least 2.7-fold higher frequency than next most
common clone). One sample exhibited an oligoclonal reper-
toire with no clearly dominant sequence. In 9/9 cases with
paired CD138-enriched samples, the dominant sequences in
the enriched and un-enriched samples were identical, indi-
cating successful identiﬁcation of the malignant clonal Ig
rearrangements in the un-enriched sample. Results were
largely consonant with clinical data, though in one IgG-l
MM sample, no dominant, productive l rearrangement was
detected, and in one IgG-k MM sample, no dominant, pro-
ductive heavy chain rearrangement was detected. This may
be due to mutations at primer-binding sites in these rear-
rangements. In both cases, alternative clone-tracking se-
quences were available from the other loci (i.e., IgH in the
ﬁrst case and k in the second). In 7/12 cases, >1 dominant
sequence among the IgH (VDJ and DJ), k, and l rearrange-
ments was identiﬁed that would be suitable for longitudi-
nally tracking the malignant clone.
Conclusion: HTS of Ig heavy and light chain rearrangements
can successfully identify the MM clone in clinical specimens,
including those with low MM burden. Application of this
technique to MRD evaluation in MM warrants further
development.
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Backgrounds: Despite recent improvements in the therapy
of mantle cell lymphoma, relapsed and refractory disease
still portends a dismal prognosis. Allogeneic stem cell
transplantation (allo-SCT) represents the only potentially
curative therapy in this setting. The aim of this report was to
evaluate the results of reduced-intensity-conditioning (RIC)
allo-SCT in a retrospective cohort of patients from a single
institution.
Patients and Methods: Twenty-nine patients (median age
58 years, range 34-71) undergoing RIC allo-SCT from April
1999 to May 2013 are included in this retrospective analysis.
Themedian number of previous lines of therapywas 5 (range
1-6) with 13 (45%) of patients having previously failed an
autologous SCT. Twenty-six patients (90%) had chemo-
sensitive disease at allo-SCT (CR¼17, PR¼9) and 3 (10%) had
stable disease. The second line International Prognostic In-
dex (sIPI) was 0 in 19 patients (65%) and 1 in 9 patients
(31%). Data was missing in 1. RIC regimens included cyclo-
phosphamide/ ﬂudarabine/ TBI 200cGy with (n¼17) or
without (n¼4) peri-allo-SCT rituximab and melphalan/ ﬂu-
darabine with (n¼6) or without (n¼2) alemtuzumab. All
patients received unmodiﬁed grafts from a matched related
(n¼12), matched unrelated (n¼10) or mismatched unrelated
(n¼7) donor. Progression-free (PFS) and overall (OS) survival
were calculated from the time of allo-SCT. Kaplan-Meier
survival curves and a permutation-based logrank test were
used to compare PFS and OS based on alemtuzumab use and
the sIPI.
Results: All but one patient engrafted with full donor
chimerism. The cumulative incidences (CI) of grade II-IV
acute GVHD at days +100 and +180were 36% (95%CI: 19-53%)
and 46% (95%CI: 27-64%), respectively. The CI of chronic
GVHD at 1 and 2 years was 20% (95%CI: 7-38%) and 29% (95%
CI: 12-49%), respectively. The CI of progression of disease and
non-relapse mortality at 2 years were 32% (95%CI: 15-51%)
and 19% (95%CI: 7-37%), respectively. With a median follow-
Figure 2. PFS is decreased in patients with sIPI  1
MAC (n¼74) RIC (n¼23) p-
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(95% CI)
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aGVHD gr 2-4
100 days
180 days
50% (39%-62%)
54% (43%-66%)
aGVHD gr 2-4
100 days
180 days
39% (22%-63%)
48% (29%-70%)
0.49
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100 days
180 days
34% (24%-46%)
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aGVHD gr 3-4
100 days
180 days
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0.12
cGVHD
1 year
2 years
32 %( 22%-47%)
35 %( 24%-49%)
cGVHD
1 year
2 years
38% (18%-70%)
38% (18%-70%)
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TRM
100 days
1 year
2 years
12% (6%-22%)
18% (11%-29%)
23% (15%-35%)
TRM
100 days
1 year
2 years
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22% (9%-46%)
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Relapse
1 year
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33 %( 23%-45%)
Relapse
1 year
2 years
43% (26%-67%)
43% (26%-67%)
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OS
1 year
2 years
53% (42%-65%)
43% (33%-56%)
OS
1 year
2 years
39% (24%-65%)
35% (20%-61%)
0.29
PFS
1 year
2 years
46% (36%-59%)
40% (31%-53%)
PFS
1 year
2 years
30% (16%-56%)
30% (16%-56%)
0.41
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OS and PFS are 64% (95%CI: 47-86%) and 49% (95%CI: 32-
73%), respectively. In vivo T cell-depletionwith alemtuzumab
was associated with a markedly reduced 2-year PFS (0% vs
64%, p¼0.008) (Figure 1). Conversely, a sIPI at transplantation
<1 was associated with a much improved 2-year PFS (65% vs
13%, p¼0.021) compared to higher sIPI values (Figure 2).
Similarly, 2-year OS was also signiﬁcantly reduced with
alemtuzumab (33% vs 74%, p¼0.016) and in patients with sIPI
1 (39% vs 76%, p¼0.036).
Conclusions: RIC allo-SCT is a feasible and effective strategy
in patients with relapsed and refractory mantle cell lym-
phoma. High sIPI and use of alemtuzumab in the condi-
tioning regimen are associated with markedly inferior PFS.
Higher risk disease and the likely loss of graft-versus-lym-
phomawith alemtuzumab predict likelihood of failure of RIC
allo-SCT in relapsed and refractory MCL patients.80
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The treatment of advanced refractory DLBCL remains a major
challenge. High dose therapy with autologous stem cell
transplant (HDT/ASCT) has a limited role only in chemo-
sensitive relapsed disease, with a curative potential of 25-
50%. No therapy has proven to be effective long-term for
advanced chemo-refractory DLBCL. Although allo-HCT has
curative potential, historically, the outcomes remain unsat-
isfactory due to high treatment related mortality (TRM) after
myeloablative conditioning (MAC), high relapse rate after
reduced-intensity conditioning (RIC) regimens and theconcern for a less potent graft-versus-lymphoma effect (GVL)
A total of 97 DLBCL patients (pts) [M64:F33] undergoing allo-
HCT at UM between 1996 and 2011 were retrospectively
evaluated. The median age was 52 yrs (range, 23-70). Sev-
enty-four pts (76%) received a MAC [CVB in 49 pts (50%),
FluBu4 in 13 pts (13%), others in 12 (12%)]; 23 pts received
RIC with FluBu2 (24%); 79 pts (81%) were 8/8 HLA-matched.
Only 18 pts (19%) had prior HDT/ASCT. Donor sources were
58 related, 6 mismatched (MM), and 39 unrelated, 12 MM.
Stem cell sources were peripheral blood in 89%, bone
marrow in 10% and cord blood in 1%. GVHD prophylaxis was
tacrolimus/ mini-methotrexate in 71 pts (73%), tacrolimus/
MMF in 16 pts (17%) and others in 10 pts (10%). Fifty-ﬁve pts
(57%) had chemo-sensitive disease at transplant; 22 pts
(23%) had transformed DLBCL.
With a median follow-up time of 12 months (range, 1.6-194),
the cumulative incidences of grade 2-4, grade 3-4 acute
GVHD, chronic GVHD, TRM, relapse, OS and PFS were not
statistically different between the MAC and RIC cohorts
(Table). Relapse rate remained high in both groups. Chemo-
sensitivity, donor source and type of DLBCL had no impact on
survival.
In summary, allogeneic HCT for advanced DLCBL is feasible,
with acceptable TRM. Although, relapse is a major issue, allo-
HCT provides these heavily pretreated pts with a platform to
combine the GVL effect with other strategies tomaximize the
potential of long-term disease-free survival.PEDIATRIC DISORDERS81
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